A Phase 3 interventional study of Pentosan Polysulfate Sodium twice weekly and Placebo in Osteoarthritis, Knee, sponsored by Paradigm Biopharmaceuticals Ltd.. Active, not recruiting at 57 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-01.
Sponsored by Paradigm Biopharmaceuticals Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 796 studies in Osteoarthritis, Knee with a site in United States — 109 open to participants now, 152 under way, 15 of them phase 3. Osteoarthritis, Knee · United States.
Among the 796 studies in Osteoarthritis, Knee with a site in United States, this one is the 62nd largest by planned enrollment of the 691 interventional ones that give a count, is one of 37 that started in 2025, is one of 76 in phase 3, reaches primary completion later than 83 of the 151 other live ones, and was the 748th registered.
3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.
Browse Osteoarthritis, Knee studies →109 of the 796 studies in Osteoarthritis, Knee with a site in United States are open now. Recruiting first, the newest first:
Lucas R. Cusumano, MD · Sites in United States
Ages 40+
VA Office of Research and Development · Sites in United States
Ages 18+
Pfizer · Sites in United States
Ages 18+
Pfizer · Sites in United States, Canada
Ages 18+
Margaret L Gourlay, MD, MPH · Sites in United States
Ages 50–64
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
796 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 60 · Phase 2 146 · Phase 3 89 · Phase 4 59
First in 1977; this study’s year is marked. 37 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 466 is above the median of 68 across 2,719 interventional studies indexed under Osteoarthritis, Knee.
Median enrollment 72 across the 691 interventional studies, 100 across the 101 observational. Of the 566 that completed or were terminated, 247 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
265 of 796 have an industry lead sponsor. The 10 most frequent:
Paradigm Biopharmaceuticals Ltd. is the lead sponsor of 2 studies on the registry; none are open to participants now.
Paradigm Biopharmaceuticals Ltd. has 2 studies filed under Osteoarthritis, Knee — fewer than ten, so there is no comparison to draw.
54 of the studies in Osteoarthritis, Knee with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07226258Phase 3Saol Therapeutics IncPhase III Study to Assess the Safety and Efficacy of SL1002 for Osteoarthritis Knee Pain | 2026-11-30 |
| NCT07219771Phase 3Doron Therapeutics Inc.A Study to Evaluate the Efficacy and Safey of PTP-001 (MOTYS™) in Knee Osteoarthritis Patients (MOTION-P) | 2027-06-30 |
| NCT06917404Phase 3Paradigm Biopharmaceuticals Ltd.A Study to Investigate the Treatment Effect of Subcutaneous Injections of Pentosan Polysulfate Sodium Compared With Placebo in Adult Participants With Knee Osteoarthritis Pain. | 2027-07 |
| NCT04368806Phase 3Nature Cell Co. Ltd.A Phase 2b/3a Study to Evaluate the Efficacy and Safety of JointStem in Patients Diagnosed as Knee Osteoarthritis | 2027-08-06 |
| NCT07151417Phase 3Walter Reed National Military Medical CenterUse of Corticosteroid in Intraopertive Injections in Total Knee Replacement Surgery. | 2027-08-31 |
Add all 54 to your calendar (.ics) → With an account.
Among the 796 studies in Osteoarthritis, Knee with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to measure the change in pain and function with subcutaneous injections of pentosan polysulfate sodium (PPS) compared with subcutaneous injections of placebo in participants with knee OA pain.
Study details include:
This is a randomised, double-blind, placebo-controlled, multicenter study that will evaluate the dose and treatment effect of PPS in participants with knee OA pain.
Participants will be randomised 1:1 to receive twice-weekly subcutaneous (SC) injections of 2 mg/kg PPS or placebo for 6 weeks.
An interim analysis for a potential early conclusion is planned after approximately 50% of participants complete Day 112.
The primary analysis will be conducted when all participants complete Day 112. A final analysis will be conducted when the last participant reaches Day 404.
The maximum duration for each participant is up to 64 weeks, which includes
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Chronic medical conditions including but not limited to those stated below requiring medical regime changes within 60 days before Day 1.
Concurrent unstable peripheral, cardiac, and cerebral vascular disease, poorly controlled and asthma, coagulopathies, uncontrolled neurological conditions, active tuberculosis, active infections, symptomatic cardiac arrhythmias, adrenal insufficiency (primary or central), nephrotic syndrome, cirrhosis ( stage B or C), Gilbert syndrome, uncontrolled diabetes, and uncontrolled hypothyroidism or hyperthyroidism, or mental or emotional disorders that preclude reliable study participation.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pentosan polysulfate sodium 2mg/kg twice weekly for 6 weeks
Drug: Pentosan Polysulfate Sodium twice weekly
Placebo (Sodium Chloride Injection, 0.9%) twice weekly for 6 weeks
Drug: Placebo
Subcutaneous injection, 2 mg/kg twice weekly for 6 weeks
Placebo, subcutaneous injection, twice weekly for 6 weeks
Change from baseline at Day 112 in knee pain as assessed by the weekly average of daily pain (ADP) score on the numerical rating scale (NRS) 11-point (0-10) scale.
The NRS is an 11-point unidimensional scale for self-report of pain. The participant selects a whole number (0-10) that best reflects the intensity of their pain. The anchors are 0=no pain and 10=extreme pain/worst possible pain. It is often categorised into no pain=0, mild pain=1-3, moderate pain=4-6, severe pain=7-10. Participants will be asked to consider their average pain over the last 24 hours.
Time frame: Baseline, Daily to Day 112
Change from baseline in function as assessed by the average functional subscale score of the WOMAC NRS 3.1 Index
The WOMAC NRS 3.1 Index is a validated, self-administered, health status questionnaire that assesses pain, stiffness, and function in patients with hip or knee OA (Bellamy et al., 1988). The WOMAC NRS 3.1 Index consists of 24 questions and produces 3 subscale scores for pain (5 questions), stiffness (2 questions), and function (17 questions) and a total score that summarises overall disability. Each question is scored from 0 to 10 using a standardised 11-point NRS. Each subscale score and the total score will be averaged to provide subscale and total scores between 0 and 10. Participants are to consider their last 4 hours when answering the questions.
Time frame: Measured at 20 timepoints from Day 1 to 404.
Change from baseline in knee pain as assessed by the average pain subscale score of the WOMAC NRS 3.1 Index
The WOMAC NRS 3.1 Index is a validated, self-administered, health status questionnaire that assesses pain, stiffness, and function in patients with hip or knee OA (Bellamy et al., 1988). The WOMAC NRS 3.1 Index consists of 24 questions and produces 3 subscale scores for pain (5 questions), stiffness (2 questions), and function (17 questions) and a total score that summarises overall disability. Each question is scored from 0 to 10 using a standardised 11-point NRS. Each subscale score and the total score will be averaged to provide subscale and total scores between 0 and 10. Participants are to consider their last 4 hours when answering the questions.
Time frame: Measured at 20 timepoints from Day 1 to 404.
Change from baseline in knee pain as assessed by the weekly average of daily pain (ADP) score on the numerical rating scale (NRS) 11-point (0-10) scale.
The NRS is an 11-point unidimensional scale for self-report of pain. The participant selects a whole number (0-10) that best reflects the intensity of their pain. The anchors are 0=no pain and 10=extreme pain/worst possible pain. It is often categorised into no pain=0, mild pain=1-3, moderate pain=4-6, severe pain=7-10. Participants will be asked to consider their average pain over the last 24 hours.
Time frame: Measured at 21 timepoints from Screening to Day 404.
Change from baseline in Patient Global Impression of Change (PGIC)
The PGIC is a self-administered question that rates participants' overall improvement in chronic pain since beginning treatment from 1 "no change (or condition has worsened)" to 7 "a great deal better" in response to the question "Since beginning treatment, how would you describe the change (if any) in activity, limitation, symptoms, emotions, and overall QoL related to your arthritis".
Time frame: Measured at 10 timepoints from Days 39 to 404.
Change from baseline in knee stiffness as assessed by the average stiffness subscale score of the WOMAC NRS 3.1 Index
The WOMAC NRS 3.1 Index is a validated, self-administered, health status questionnaire that assesses pain, stiffness, and function in patients with hip or knee OA (Bellamy et al., 1988). The WOMAC NRS 3.1 Index consists of 24 questions and produces 3 subscale scores for pain (5 questions), stiffness (2 questions), and function (17 questions) and a total score that summarises overall disability. Each question is scored from 0 to 10 using a standardised 11-point NRS. Each subscale score and the total score will be averaged to provide subscale and total scores between 0 and 10. Participants are to consider their last 4 hours when answering the questions.
Time frame: Measured at 20 timepoints from Day 1 to 404.
Change from baseline overall as assessed by the overall score of the WOMAC NRS 3.1 Index
The WOMAC NRS 3.1 Index is a validated, self-administered, health status questionnaire that assesses pain, stiffness, and function in patients with hip or knee OA (Bellamy et al., 1988). The WOMAC NRS 3.1 Index consists of 24 questions and produces 3 subscale scores for pain (5 questions), stiffness (2 questions), and function (17 questions) and a total score that summarises overall disability. Each question is scored from 0 to 10 using a standardised 11-point NRS. Each subscale score and the total score will be averaged to provide subscale and total scores between 0 and 10. Participants are to consider their last 4 hours when answering the questions.
Time frame: Measured at 20 timepoints from Day 1 to 404.
Proportion of participants with ≥30% and ≥50% pain reduction from baseline as assessed by the average pain subscale score of the WOMAC NRS 3.1 Index.
The WOMAC NRS 3.1 Index is a validated, self-administered, health status questionnaire that assesses pain, stiffness, and function in patients with hip or knee OA (Bellamy et al., 1988). The WOMAC NRS 3.1 Index consists of 24 questions and produces 3 subscale scores for pain (5 questions), stiffness (2 questions), and function (17 questions) and a total score that summarises overall disability. Each question is scored from 0 to 10 using a standardised 11-point NRS. Each subscale score and the total score will be averaged to provide subscale and total scores between 0 and 10. Participants are to consider their last 4 hours when answering the questions.
Time frame: Measured at 20 timepoints from Day 1 to 404.
Proportion of participants with ≥30% and ≥50% improvement in function from baseline as assessed by the average pain subscale score of the WOMAC NRS 3.1 Index.
The WOMAC NRS 3.1 Index is a validated, self-administered, health status questionnaire that assesses pain, stiffness, and function in patients with hip or knee OA (Bellamy et al., 1988). The WOMAC NRS 3.1 Index consists of 24 questions and produces 3 subscale scores for pain (5 questions), stiffness (2 questions), and function (17 questions) and a total score that summarises overall disability. Each question is scored from 0 to 10 using a standardised 11-point NRS. Each subscale score and the total score will be averaged to provide subscale and total scores between 0 and 10. Participants are to consider their last 4 hours when answering the questions.
Time frame: Measured at 20 timepoints from Day 1 to 404.
Number of days of rescue medication used
In case of inadequate pain relief, either acetaminophen/paracetamol up to 3000 mg per day or topical analgesics, up to 4 days in a week may be taken as rescue medication between day 1 and Day 404. Participants will record all use of rescue and other pain medications/therapies in their electronic diary.
Time frame: Recorded from Day 1 to 404
Change from baseline in QoL as assessed by EQ-5D-5L.
The EQ-5D-5L questionnaire is a self-assessed, health related, QoL questionnaire consisting of the EQ-5D descriptive system and the EQ VAS. The descriptive system comprises of five dimensions, where each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The patient is asked to indicate their health state by ticking the box next to the most appropriate statement in each of the five dimensions.
Time frame: Measured at 13 timepoints from Days 1 to 404
Change from baseline in cartilage volume and thickness on Magnetic Resonance Imaging (MRI).
Gadolinium MRI images will be taken to measure changes in cartilage volume and thickness.
Time frame: Measured at Days 1, 168 and 404.
Change from baseline in joint synovitis/effusion volume on Magnetic Resonance Imaging (MRI).
Gadolinium MRI images will be taken to measure changes in joint synovitis/effusion volume,.
Time frame: Measured at Days 1, 168 and 404.
Change from baseline in subchondral BML area and volume on Magnetic Resonance Imaging (MRI).
Gadolinium MRI images will be taken to measure changes in subchondral BML area and volume,.
Time frame: Measured at Days 1, 168 and 404.
Change from baseline in bone shape/osteophytes on Magnetic Resonance Imaging (MRI).
Gadolinium MRI images will be taken to measure changes in bone shape/osteophytes.
Time frame: Measured at Days 1, 168 and 404.
Change from baseline in joint space width on X-ray.
X-ray for comparison of joint space width
Time frame: Measured at Days 1 and 404.
OMERACT-OARSI Responder Index response rate
OMERACT-OARSI-Outcome Measures in Rheumatology-Osteoarthritis Research Society International. Participants are considered as an OMERACT-OARSI responder: if the change (improvement) from baseline to day of interest was greater than or equal to \>= 50 percent and \>= 2 units in either WOMAC pain sub-scale or physical function sub-scale score; if change (improvement) from baseline to week of interest was \>=20 percent and \>=1 unit in at least 2 of the following: 1) WOMAC pain sub-scale score, 2) WOMAC physical function sub-scale score, 3) Patient Global Impression of Change (PGIC).
Time frame: Measured at 10 timepoints from Days 39 to 404.
Change from baseline in Work Productivity and Activity Impairment (WPAI) questionnaire score
The WPAI questionnaire (WPAI:OA-knee) is a validated self-administered questionnaire that assesses work impairment due to OA . The questionnaire gathers information on employment status, hours worked, hours missed due to OA, and hours missed for any other reasons.
Time frame: Measured at 10 timepoints from Day 39 to 404.
Incidence of treatment-emergent adverse events (TEAEs), including serious adverse events (SAEs)
An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. An SAE is any untoward medical occurrence that at any dose results in one or more of the following outcomes: death; life-threatening; requires in-patient hospitalization or prolongation of an existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect; is an important medical event. Treatment-emergent means events occurring between the first dose of study drug and up to Day 404 that were absent before treatment or that worsened relative to pre-treatment state.
Time frame: From enrollment to Day 404
Incidence of treatment-emergent clinical abnormalities
Treatment-emergent clinical laboratory abnormalities are abnormalities in laboratory results between the first dose of study drug and up to Day 404 that were absent before treatment or that worsened relative to pre-treatment state
Time frame: From enrollment to Day 404
Exploratory: Characterize the AUC profile of single and multiple doses based on sparse blood sampling. (pharmacokinetic subset only)
Blood samples for assay of plasma PPS concentration will be obtained from a subset of patients before dosing and 2, 4, and 6 hours after dosing on study Days 1, 15 and 39. On other days, a pre-dose sample will be collected. Samples will be assayed using a sensitive, validated bioanalytical method. Plasma concentrations of PPS will be tabulated by time and participant and inspected for relationship to dose during titration and stable treatment phases.
Time frame: Days 1, 15 and 39 - pre-dose and 2, 4, and 6 hours. Pre-dose on day 4, 8, 11, 18, 22, 25, 29, 32, 36 and 39
Exporatory: Number of participants with an Anti-Drug-Antibody (ADA) response after treatment and correlation with clinical events.
Human serum ADA samples will be analyzed for the presence or absence of anti-drug-antibodies by using a semi-quantitative enzyme linked immunosorbent assay (ELISA).
Time frame: Baseline, Days 11, 25, 39, 56 and 84.
Exploratory: Change from baseline in serum biomarkers, including but not limited to, COMP, aggrecan ARGS, CRTAC-1, PRO-C2 PIIBNP, NTx-Ⅰ, and HA.
ARGS-(aggrecan) alanine-arginine-glycine-serine; COMP-cartilage oligomeric matrix protein; CRTAC-1-cartilage acidic protein-1; HA-hyaluronic acid; NTx-1-N-terminal telopeptide of type I collagen; PIIBNP-N-terminal propeptide of type II collagen; PRO-C2-type II collagen C-terminal propeptide.
Time frame: Measured at 11 timepoints from Day 4 to 168.
Exploratory: Change from baseline of cartilage volume and thickness and whether these correlate with clinical pain outcomes.
The correlation co-efficient of changes in cartilage volume and thickness as measured on MRI and pain clinical outcomes.
Time frame: Screening, Day 168 and 404
Exploratory: Change from baseline of subchondral BMLs, and whether these correlate with clinical pain outcomes.
The correlation co-efficient of changes in subchondral BMLs as measured on MRI and pain clinical outcomes.
Time frame: Screening , Day 168 and 404
Exploratory: Change from baseline of bone shape and whether these correlate with clinical pain outcomes.
• The correlation co-efficient of changes in bone shape changes as measured on MRI and pain clinical outcomes
Time frame: Screening , Day 168 and 404
Exploratory: Change from baseline of joint space width and whether these correlate with clinical pain outcomes.
The correlation co-efficient between changes in joint space width as measured on X-Ray and clinical pain outcomes.
Time frame: Screening and 404
Plan to share: No
No publications or documents are linked to this record.
Started May 2025 (actual). Primary completion is estimated for Jul 2027, 26 months after the start.
Of 65 industry-sponsored phase 3 interventional studies under Osteoarthritis, Knee, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 27. This study's planned 26 months is above that.
Counting every sponsor, half of 101 studies reached it within 22 months; a quarter within 15 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Paradigm Biopharmaceuticals Ltd.